selected publications
-
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
JAMA oncology.
2019
Academic Article
GET IT
Times cited: 335 -
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients.
Cancer cell.
2018
Academic Article
GET IT
Times cited: 131 -
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
JAMA oncology.
2018
Academic Article
GET IT
Times cited: 142 -
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2016
Academic Article
GET IT
Times cited: 147 -
Targeting the androgen receptor in prostate and breast cancer: several new agents in development.
Endocrine-related cancer.
2015
Review
GET IT
Times cited: 78 -
Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.
2014
GET IT
Times cited: 24 -
High-risk prostate cancer-classification and therapy.
Nature reviews. Clinical oncology.
2014
Review
GET IT
Times cited: 273 -
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.
European urology.
2014
Academic Article
GET IT
Times cited: 34 -
Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective.
Cancer.
2013
Academic Article
GET IT
Times cited: 24 -
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
The Lancet. Oncology.
2013
Review
GET IT
Times cited: 142 -
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.
Journal of oncology practice.
2013
Academic Article
GET IT
Times cited: 24 -
Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.
Cancer.
2013
Academic Article
GET IT
Times cited: 21 -
Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?.
Seminars in oncology.
2013
Review
GET IT
Times cited: 32 -
Targeting bone physiology for the treatment of metastatic prostate cancer.
Clinical advances in hematology & oncology : H&O.
2013
Review
GET IT
Times cited: 11 -
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.
Current treatment options in oncology.
2012
Review
GET IT
Times cited: 27 -
Low bone mineral density in adolescents with beta-thalassemia.
Annals of the New York Academy of Sciences.
2005
Academic Article
GET IT
Times cited: 61 -
Low bone mass in prepubertal children with thalassemia major: insights into the pathogenesis of low bone mass in thalassemia.
Journal of pediatric endocrinology & metabolism : JPEM.
2004
Academic Article
GET IT
Times cited: 44